Soleno Therapeutics INC 8-K filings

SolenO Therapeutics, Inc. has been acquired by Neurocrine Biosciences, Inc. through a tender offer and subsequent merger, with shareholders receiving $53.00 per share.

Soleno Therapeutics has voluntarily withdrawn its European marketing application for VIOKAT, a treatment for Prader-Willi syndrome, citing strategic business reasons.

Neurocrine Biosciences has entered into a definitive agreement to acquire Soleno Therapeutics for $53.00 per share in cash.

Soleno Therapeutics, Inc. has adopted amended and restated bylaws to update stockholder advance notice provisions, reflect Delaware law changes, and include a forum selection clause.

Soleno Therapeutics announced the appointment of Jennifer Fulk as its new Chief Financial Officer, succeeding James Mackaness who will retire by the end of March 2026.

Soleno Therapeutics reported strong fourth quarter and full-year 2025 financial results, achieving profitability and significant progress in the U.S. launch of VYKAT XR for Prader-Willi syndrome.

Soleno Therapeutics' Board approved significant increases in executive base salaries, cash bonuses, and equity awards for fiscal year 2026, alongside a new Key Executive Change in Control and Severance Plan.

Soleno Therapeutics announced preliminary unaudited financial and operating results for Q4 and full-year 2025, highlighting strong VYKAT XR sales and market penetration.

Soleno Therapeutics announced a $100 million accelerated share repurchase program and amended its loan facility to permit the transaction, while also making previously committed loans uncommitted.

Soleno Therapeutics reported a profitable third quarter 2025 with $66.0 million in VYKAT XR revenue and a positive net income of $26.0 million, driven by a successful product launch.

Soleno Therapeutics strengthens its Board and Audit Committee with the appointment of Mark W. Hahn, a seasoned biopharmaceutical finance executive, to support the commercial launch of VYKAT XR.

Soleno Therapeutics acknowledged a reported patient death in the FDA's adverse event system, stating it was not related to VYKAT XR treatment.

Soleno Therapeutics highlights strong VYKAT XR launch metrics and a robust financial position, extending cash runway beyond commercialization.

Soleno Therapeutics announced its second quarter 2025 financial results, highlighting a successful initial U.S. launch of VYKAT XR with $32.7 million in product revenue and a significant post-quarter capital raise.

Soleno Therapeutics, Inc. announced the pricing of a public offering of common stock expected to raise $200 million, with an option for an additional $30 million, primarily to fund the commercialization of its recently FDA-approved Prader-Willi syndrome drug, VYKAT™ XR.

Soleno Therapeutics announced preliminary unaudited financial and operational results for the second quarter ended June 30, 2025, projecting net revenue between $31.0 million and $33.0 million from VYKATTM XR sales and reporting approximately $293.8 million in cash, cash equivalents, and marketable securities.

Soleno Therapeutics, Inc. announced the successful re-election of two Class II directors and the ratification of its independent public accounting firm at its 2025 Annual Meeting of Stockholders, with a high quorum of 94.7%.

Soleno Therapeutics reports FDA approval and U.S. launch of VYKAT XR for Prader-Willi syndrome, along with Q1 2025 financial results showing increased operating expenses and a net loss.

Soleno Therapeutics has replaced its independent registered public accounting firm, with CBIZ CPAs taking over from Marcum LLP, effective April 18, 2025.

Soleno Therapeutics announces FDA approval of VYKAT XR (diazoxide choline) extended-release tablets for treating hyperphagia in adults and children with Prader-Willi syndrome (PWS).

Soleno Therapeutics reported its fourth quarter and full-year 2024 financial results, highlighting regulatory progress, commercial readiness, and corporate developments.

Soleno Therapeutics has approved salary increases, cash bonuses, and equity awards for its named executive officers for fiscal years 2025 and 2024.

Soleno Therapeutics has entered into a loan agreement with Oxford Finance for up to $200 million to support the commercialization of its Prader-Willi syndrome treatment.

The FDA has extended the review period for Soleno Therapeutics' DCCR drug for Prader-Willi Syndrome by three months, with a new target action date of March 27, 2025.

Soleno Therapeutics reports FDA acceptance of its NDA for DCCR and third quarter 2024 financial results, highlighting increased R&D and G&A expenses due to stock-based compensation.

Soleno Therapeutics has announced the resignation of its Chairman due to health reasons, the appointment of a new director, and changes to committee leadership.

Soleno Therapeutics announced the submission of a New Drug Application (NDA) to the FDA for Diazoxide Choline Extended-Release (DCCR) for Prader-Willi Syndrome (PWS) and reported its second quarter 2024 financial results.

Soleno Therapeutics has entered into an agreement with Jefferies LLC to sell up to $150 million of its common stock through an at-the-market offering.

Soleno Therapeutics granted performance-based restricted stock units to all employees, including named executive officers, with vesting tied to key milestones such as FDA acceptance and approval of their New Drug Application.

Soleno Therapeutics has submitted a New Drug Application to the FDA for DCCR extended-release tablets, aimed at treating Prader-Willi Syndrome.